<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="270">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04324463</url>
  </required_header>
  <id_info>
    <org_study_id>PHRI.ACT.COVID19</org_study_id>
    <nct_id>NCT04324463</nct_id>
  </id_info>
  <brief_title>Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial</brief_title>
  <acronym>ACT COVID19</acronym>
  <official_title>Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      ACT is a randomized clinical trial to assess therapies to reduce the clinical progression of
      COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ACT COVID-19 program consists of two parallel trials evaluating azithromycin and
      chloroquine therapy (ACT) versus usual care in outpatients and inpatients who have tested
      positive for COVID-19. The trial is an open-label, parallel group, randomized controlled
      trial with an adaptive design. Adaptive design features include adaptive intervention arms
      and adaptive sample size based on new and emerging data.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label, parallel group randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Outpatients: Hospital Admission or Death</measure>
    <time_frame>Up to 6 weeks post randomization</time_frame>
    <description>In outpatients with COVID-19, the occurrence of hospital admission or death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inpatients: Invasive mechanical ventilation or mortality</measure>
    <time_frame>Up to 6 weeks post randomization</time_frame>
    <description>Patients intubated or requiring imminent intubation at the time of randomization will only be followed for the primary outcome of death.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Coronavirus</condition>
  <condition>Severe Acute Respiratory Syndrome</condition>
  <arm_group>
    <arm_group_label>Azithromycin and Chloroquine Therapy (ACT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chloroquine (Adults with a bodyweight ≥ 50 kg: 500 mg twice daily for 7 days; Adults with a bodyweight &lt; 50 kg: 500 mg twice daily on days 1 and 2, followed by 500 mg once daily for days 3-7), plus Azithromycin (500 mg on day 1 followed by 250 mg daily for 4 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No constraints for treating physicians on the therapies within the standard of care arm. All key co-interventions will be documented.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>oral medication</description>
    <arm_group_label>Azithromycin and Chloroquine Therapy (ACT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine</intervention_name>
    <description>oral medication</description>
    <arm_group_label>Azithromycin and Chloroquine Therapy (ACT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years of age

          -  Informed consent

          -  COVID-19 confirmed by established testing

        Exclusion Criteria:

          -  Known glucose-6-phosphate dehydrogenase (G6PD) deficiency

          -  Contra-indication to chloroquine or azithromycin

          -  Already receiving chloroquine or azithromycin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Whitlock, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emilie Belley-Cote, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ACT COVID-19 Study Coordinator</last_name>
    <phone>905-297-3479</phone>
    <email>ACT.ProjectTeam@PHRI.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>ACT COVID-19 Study Coordinator</last_name>
      <email>ACT.ProjectTeam@PHRI.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 25, 2020</study_first_submitted>
  <study_first_submitted_qc>March 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2020</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>chloroquine</keyword>
  <keyword>azithromycin</keyword>
  <keyword>coronavirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

